


## AMENDMENTS TO THE CLAIMS

Please delete all prior lists of claims in the application and insert the following list of claims:

1-4 (CANCELED).

5. (CURRENTLY AMENDED) A compound of structural formula (I) for use as an activator of histone acetyltransferases:



wherein:

R<sup>1</sup> is selected from the group consisting of **hydrogen**, C<sub>1</sub>- to C<sub>16</sub>-alkyl and C<sub>1</sub>- to C<sub>16</sub>-alkene;

R<sup>2</sup> is selected from the group consisting of hydrogen, and C<sub>1</sub>- to C<sub>6</sub>-alkyl;

R<sup>3</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>5</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>,

F, Cl, I, and;

R<sup>6</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>7</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN; and

R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are independently selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>16</sub>-alkyl, C<sub>1</sub>- to C<sub>16</sub>-alkene, and C<sub>1</sub>- to C<sub>16</sub>-alkoxy; and salts thereof.

6. (CURRENTLY AMENDED) The compound of claim 5, wherein:

R<sup>1</sup> is selected from the group consisting of ~~methyl, ethyl~~, n-propyl, isopropyl, n-butyl, t-butyl, C<sub>8</sub>H<sub>18</sub>, C<sub>15</sub>H<sub>26</sub>, C<sub>15</sub>H<sub>28</sub>, C<sub>15</sub>H<sub>30</sub>, and C<sub>15</sub>H<sub>32</sub>;

R<sup>2</sup> is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl;

R<sup>3</sup> is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>4</sup> is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>5</sup> is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, and I;

R<sup>6</sup> is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN; and

R<sup>7</sup> is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN.


7. (PREVIOUSLY PRESENTED) A compound selected from the group consisting of:

N-(4-nitro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;

N-(4-nitro-3-trifluoromethyl-phenyl)-2-propoxy-benzamide;  
 N-(4-nitro-3-trifluoromethyl -phenyl)-2-isopropoxy-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-6-pentadecyl-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-n-propoxy-6-pentadecyl-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-methoxy-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-methoxy-benzamide;  
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide;  
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide;  
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-  
 benzamide;  
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;  
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;  
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;  
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;  
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 N-(4-bromo-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-bromo-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-bromo-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;  
 N-(4-bromo-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 N-(4-carboxylic-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;  
 N-(4-carboxylic-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;  
 N-(4-carboxylic-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;  
 N-(4-carboxylic-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide; and  
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;  
 and salts thereof.

8. (CURRENTLY AMENDED) A compound of structural formula (I):



wherein R<sup>1</sup> is selected from the group consisting of C<sub>14</sub>- to C<sub>16</sub>-alkyl and C<sub>14</sub>- to C<sub>16</sub>-alkenyl  
~~R<sup>2</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are defined such that the ring moiety to which R<sup>1</sup>, R<sup>2</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are attached defines a moiety selected from the group consisting of anacardic acid, anacardic aldehyde, anacardic alcohol, 2-ethoxy-6-pentadecyl benzoic acid, cardanol, and cardol;~~

**R<sub>2</sub> is selected from the group consisting of hydrogen, methyl, and ethyl;**

R<sup>3</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>5</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, and I;

R<sup>6</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN; ~~and~~


R<sup>7</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

**R<sup>8</sup> and R<sup>10</sup> are hydrogen; and**

**R<sup>9</sup> is selected from the group consisting of hydrogen and hydroxy;**

and salts thereof.

9. (CURRENTLY AMENDED) A compound of structural formula (I):



wherein R<sup>1</sup> is selected from the group consisting of C<sub>12</sub>- to C<sub>16</sub>-alkyl and C<sub>12</sub>- to C<sub>16</sub>-

alkene, ~~and R<sup>2</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are hydrogen:~~

R<sup>2</sup> is selected from the group consisting of hydrogen, and C<sub>1</sub>- to C<sub>6</sub>-alkyl;

R<sup>3</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>5</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, and I;

R<sup>6</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN;

R<sup>7</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>6</sub>-alkyl, CF<sub>3</sub>, CCl<sub>3</sub>, Cl<sub>3</sub>, F, Cl, I, and CN; and

R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are independently selected from the group consisting of hydrogen, C<sub>1</sub>- to C<sub>16</sub>-alkyl, C<sub>1</sub>- to C<sub>16</sub>-alkene, and C<sub>1</sub>- to C<sub>16</sub>-alkoxy; and salts thereof.

10. – 13. (CANCELED)

14. (PREVIOUSLY PRESENTED) A pharmaceutical composition for treating cancer, acquired immune deficiency syndrome (AIDS), HIV infection, and asthma, the composition comprising an anti-cancer-, anti-AIDS-, anti-HIV- or anti-asthma-effective amount of a compound of claim 5 or a pharmaceutically suitable salt thereof, in combination with a pharmaceutically suitable carrier.

15. (CANCELED)

16. (CANCELED)